Salveen Richter
Stock Analyst at Goldman Sachs
Total Price Targets
22
Stocks Covered
13
Sectors
Healthcare
Most Recent
Jan 8, 2026
Notable Calls (Last 12 Months)
Stocks Covered by Salveen Richter
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| BIIB | Biogen Inc. | $225.00 | $186.69 | +20.5% | 4 | Jan 8, 2026 |
| RCUS | Arcus Biosciences, Inc. | $16.00 | $25.66 | -37.6% | 1 | Oct 30, 2025 |
| VRTX | Vertex Pharmaceuticals Incorporated | $598.00 | $425.06 | +40.7% | 1 | Oct 21, 2024 |
| AMGN | Amgen Inc. | $369.00 | $328.69 | +12.3% | 2 | Oct 16, 2024 |
| REGN | Regeneron Pharmaceuticals, Inc. | $1292.00 | $703.72 | +83.6% | 2 | Sep 24, 2024 |
| INCY | Incyte Corporation | $60.00 | $96.41 | -37.8% | 2 | Sep 16, 2024 |
| GILD | Gilead Sciences, Inc. | $71.00 | $132.04 | -46.2% | 2 | Sep 12, 2024 |
| DNLI | Denali Therapeutics Inc. | $46.00 | $18.49 | +148.8% | 2 | Sep 3, 2024 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $370.00 | $297.62 | +24.3% | 2 | Aug 16, 2024 |
| IONS | Ionis Pharmaceuticals, Inc. | $33.00 | $75.86 | -56.5% | 1 | Jul 22, 2024 |
| RARE | Ultragenyx Pharmaceutical Inc. | $67.00 | $24.79 | +170.3% | 1 | Jun 6, 2024 |
| NTLA | Intellia Therapeutics, Inc. | $252.00 | $13.20 | +1809.1% | 1 | Aug 6, 2021 |
| FOLD | Amicus Therapeutics, Inc. | $14.00 | $14.49 | -3.4% | 1 | May 10, 2021 |
Recent Activity
- Jan 8, 2026— Set$225.00price target onBIIB(Biogen Inc.)
- Oct 30, 2025— Set$16.00price target onRCUS(Arcus Biosciences, Inc.)
- Oct 30, 2024— Set$290.00price target onBIIB(Biogen Inc.)
- Oct 21, 2024— Set$598.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Oct 16, 2024— Set$369.00price target onAMGN(Amgen Inc.)
- Sep 24, 2024— Set$1292.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Sep 16, 2024— Set$60.00price target onINCY(Incyte Corporation)
- Sep 12, 2024— Set$71.00price target onGILD(Gilead Sciences, Inc.)
- Sep 3, 2024— Set$46.00price target onDNLI(Denali Therapeutics Inc.)
- Aug 16, 2024— Set$370.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Jul 26, 2024— Set$342.00price target onBIIB(Biogen Inc.)
- Jul 22, 2024— Set$33.00price target onIONS(Ionis Pharmaceuticals, Inc.)
- Jun 6, 2024— Set$67.00price target onRARE(Ultragenyx Pharmaceutical Inc.)
- Dec 6, 2021— Set$80.00price target onGILD(Gilead Sciences, Inc.)
- Dec 6, 2021— Set$258.00price target onAMGN(Amgen Inc.)
- Dec 6, 2021— Set$271.00price target onBIIB(Biogen Inc.)
- Dec 6, 2021— Set$824.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Nov 24, 2021— Set$136.00price target onINCY(Incyte Corporation)
- Nov 22, 2021— Set$273.00price target onALNY(Alnylam Pharmaceuticals, Inc.)
- Aug 6, 2021— Set$252.00price target onNTLA(Intellia Therapeutics, Inc.)
Frequently Asked Questions
Who is Salveen Richter?
Salveen Richter is a stock analyst at Goldman Sachs covering 13 stocks primarily in Healthcare. They have issued 22 price targets since May 10, 2021.
What stocks does Salveen Richter cover?
Salveen Richter currently covers 13 stocks, including BIIB, AMGN, REGN, INCY, GILD.
What is Salveen Richter's latest price target?
Salveen Richter's most recent price target was $225.00 on BIIB (Biogen Inc.), set on Jan 8, 2026.
What is Salveen Richter's highest price target?
Salveen Richter's highest issued price target is $1292.00 on REGN, set on Sep 24, 2024.
More Analysts at Goldman Sachs
Coverage based on publicly published price targets. Not investment advice.